Pregled bibliografske jedinice broj: 1086581
EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma
EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma // The European respiratory journal. Supplement, 62 (2018), 2892, 1 doi:10.1183/13993003 (međunarodna recenzija, članak, ostalo)
CROSBI ID: 1086581 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
EBUS-TBNA for the diagnosis of intrathoracic
lymphadenopathy in patients with previously
diagnosed breast carcinoma
Autori
Piskač Živković, Nevenka ; Ljilja, Anja ; Novak Nina Petra, Tudorić Neven
Izvornik
The European respiratory journal. Supplement (0903-1936) 62
(2018);
2892, 1
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo
Ključne riječi
breast carcinoma, mediastinal lymphadenopathy, EBUS
Sažetak
The diagnostic method of endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) for the confirmation of extrathoracic malignant disease dissemination into mediastinal lymph nodes has been proven as highly efficient (sensitivity 93%, specificity 100%). The aim of this research was to carry out a retrospective study of the medical records of patients with newly developed mediastinal/hilar lymphadenopathy (ML) and previously diagnosed extrathoracic malignant disease, select the patients with previously diagnosed breast carcinoma, and analyze the results of EBUS-TBNA. The retrospective, single-center clinical observational study was conducted in the period from January 2015 to August 2017, in which the EBUS-TBNA results were analyzed for 77 patients who had met the inclusion criteria. A malignant etiology of the ML was confirmed in 39/77 patients (50.64%). Patients with previously diagnosed breast carcinoma showed a divergence within this group. A malignant etiology of the ML was confirmed in 10/14 patients (71.42%), and a benign one in 3/14 patients (21.42%). In one patient with reactive lymphadenopathy and pulmonary parenchymal infiltration, primary lung carcinoma was confirmed by thoracotomy. Two patients showed signs of reactive/granulomatous ML during chemotherapy with paclitaxel, and in one patient sarcoidosi was confirmed. To conclude, in spite of the high percentage of a malignant etiology of newly developed ML in patients with previously diagnosed breast carcinoma, their cytological verification is necessary due to the possibility of a reactive/granulomatous lymph node reaction, especially in patients undergoing chemotherapy with paclitaxel.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE